Medical device company Apyx Medical Corporation (NASDAQ:APYX) stated on Monday its impressive preliminary sales performance for the full year and fourth quarter ended 31 December 2019.
For full year 2019 , the company expects total revenue from continuing operations in a range of approximately USD27.9 to USD28.1m, a rise of approximately 67% to 68% year-over-year. Advanced Energy revenue in a range of approximately USD22.3 to USD22.6m, a growth of approximately 71% to 73% year-over-year. OEM revenue of approximately USD5.5m, which rose approximately 52% year-over-year.
In the fourth quarter of 2019, the company anticipates revenue from continuing operations in a range of approximately USD8.1 to USD8.3m, an improvement of approximately 36% to 41% year-over-year. Advanced Energy revenue of approximately USD6.6 to USD6.9m, an increase of approximately 52% to 58% year-over-year.
The OEM revenue of approximately USD1.5m was generated in the fourth quarter of 2019, a dip of approximately 7% year-over-year.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon